Curevac N.v Stock News

CureVac N.V. (NASDAQ:CVAC) traded at $49.11 at last check on Tuesday, November 30, made an upward move of 5.20% on its previous days price. Looking at the stock we see that its previous close was $46.68 with the days price range being $44.68 $47.7583. In terms of its 52-week price range, CVAC has a CureVac N.V. (NASDAQ: CVAC) Continues To Be Hot This Week? Read More »

Even a good year for stocks has its share of high-flyers that have turned into losers — or buying opportunities.

CureVac (NASDAQ:CVAC)s share price was down 5.5% during mid-day trading on Tuesday . The stock traded as low as $38.95 and last traded at $38.95. Approximately 2,099 shares changed hands during trading, a decline of 100% from the average daily volume of 963,487 shares. The stock had previously closed at $41.21. Several research analysts recently []

Vanguard Group Inc. increased its position in CureVac (NASDAQ:CVAC) by 120.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 82,368 shares of the companys stock after acquiring an additional 44,944 shares during the period. Vanguard Group Inc.s holdings in CureVac were worth $6,053,000 []

CVAC earnings call for the period ending September 30, 2021.

CureVac's (CVAC) CEO Franz-Werner Haas on Q3 2021 Results - Earnings Call Transcript

Goldman Sachs Group Inc. raised its position in CureVac (NASDAQ:CVAC) by 331.9% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 72,893 shares of the companys stock after acquiring an additional 56,017 shares during the period. Goldman Sachs Group Inc.s holdings in CureVac were worth $5,356,000 as []

(PR-inside.com) Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory reviewNature publication of promising pre-clinical results for second-generation COVID-19 vaccine candidate, CV2CoV, in study with Harvard Medical School, showing comparable immune response to a licensed mRNA vaccinePositive developments across rest of the pipeline, including pre-clinical results in molecular therapies and progress of Phase 1 study with lead candidate in oncologyRe-allocation of existing manufacturing lines and capacities to support second-generation program and streamlining of external manufacturing networkCash position of 1.06 billion as of September 30, 2021. CureVac continues to assess supplier ..

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia Gene Therapy Candidate Roche H

(PR-inside.com) TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature . The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty(R) (Pfizer/BioNTech). Neutralizing antibody levels measured following full vaccination of animals with either 12µg of CV2CoV or a 30µg standard dose of Comirnaty(R) were shown to be highly ..

TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the

CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline Plc (NYSE

CureVac BV (NASDAQ: CVAC) shares are trading lower after the company and Bayer reportedly terminated their vaccine manufacturing partnership. More news came around 1:20 pm EDT after an SEC filing sho